BRIEF published on 06/30/2026 at 19:13, 4 months 8 days ago ABIONYX Pharma obtient des fonds pour faire progresser le traitement de la septicémie ABIONYX Pharma CER-001 Traitement De La Septicémie Plateforme ApoA-I Financement Financier
PRESS RELEASE published on 06/30/2026 at 19:08, 4 months 8 days ago Inside Information / Other news releases ABIONYX Pharma scales up operations after securing resources, focusing on value creation in inflammation and sepsis treatment. Updates on pivotal clinical trial, financial visibility, and scientific platform development Financial Resources Clinical Trial ABIONYX Pharma Sepsis Inflammation Treatment
PRESS RELEASE published on 06/30/2026 at 19:08, 4 months 8 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma change d'échelle suite à la sécurisation des moyens de son ambition et ouvre un nouveau cycle de création de valeur dans les inflammations sévères et le sepsis ABIONYX Pharma Sepsis Création De Valeur Innovantes Inflammations Sévères
BRIEF published on 06/18/2026 at 07:35, 4 months 21 days ago ABIONYX Pharma Completes Successful EUR 33 Million Financing Capital Increase Bond Financing ABIONYX Pharma Fenja Capital Sepsis Research
BRIEF published on 06/18/2026 at 07:35, 4 months 21 days ago ABIONYX Pharma successfully completes its capital increase Capital Increase Clinical Trial Bond Financing Sepsis Fenja Capital
BRIEF published on 06/18/2026 at 07:35, 4 months 21 days ago ABIONYX Pharma réussit son augmentation de capital Augmentation De Capital Essai Clinique Financement Obligataire Sepsis Fenja Capital
BRIEF published on 06/18/2026 at 07:35, 4 months 21 days ago ABIONYX Pharma finalise avec succès un financement de 33 millions d'euros. Augmentation De Capital ABIONYX Pharma Fenja Capital Financement Par Obligations Recherche Sur La Septicémie
PRESS RELEASE published on 06/18/2026 at 07:30, 4 months 21 days ago Inside Information / Other news releases ABIONYX Pharma successfully completes financing, raising EUR 33 M. Capital increase and bonds financing secured, enhancing financial position for future growth and clinical trials Financing Clinical Trials Capital Increase ABIONYX Pharma Bonds Financing
PRESS RELEASE published on 06/18/2026 at 07:30, 4 months 21 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce le succès de son financement de 33 M€ pour renforcer son développement clinique et sa trésorerie. Les actionnaires historiques soutiennent l'opération Financement Trésorerie Développement Clinique Actionnaires Historiques ABIONYX Pharma
BRIEF published on 05/28/2026 at 19:11, 5 months 11 days ago ABIONYX Pharma annonce un premier trimestre stable et un financement solide pour sa croissance future. Augmentation De Capital Essais Cliniques Stabilité Financière ABIONYX Pharma Recettes 2026
Published on 11/06/2026 at 22:15, 2 days 10 hours ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 19 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 20 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 20 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/09/2026 at 08:15, 18 minutes ago EQS-Adhoc: Airbus SE: Airbus commences multi-year share buyback programme, with launch of the first tranche
Published on 11/09/2026 at 08:05, 28 minutes ago Onodrim Industries secures $300 million Series A at $1.3 billion valuation to strengthen Europe's defence and industrial foundations
Published on 11/09/2026 at 08:00, 33 minutes ago Custodian Property Income REIT plc: Further momentum with majority share-based acquisition strategy, purchasing an £11.0m property portfolio from eight syndicated investment vehicles
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 13 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
